218 related articles for article (PubMed ID: 15297418)
1. EphA2 expression is associated with aggressive features in ovarian carcinoma.
Thaker PH; Deavers M; Celestino J; Thornton A; Fletcher MS; Landen CN; Kinch MS; Kiener PA; Sood AK
Clin Cancer Res; 2004 Aug; 10(15):5145-50. PubMed ID: 15297418
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas.
Han L; Dong Z; Qiao Y; Kristensen GB; Holm R; Nesland JM; Suo Z
Gynecol Oncol; 2005 Nov; 99(2):278-86. PubMed ID: 16061279
[TBL] [Abstract][Full Text] [Related]
3. EphA2 overexpression is associated with angiogenesis in ovarian cancer.
Lin YG; Han LY; Kamat AA; Merritt WM; Landen CN; Deavers MT; Fletcher MS; Urbauer DL; Kinch MS; Sood AK
Cancer; 2007 Jan; 109(2):332-40. PubMed ID: 17154180
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma.
Xu F; Zhong W; Li J; Shanshen Z; Cui J; Nesland JM; Suo Z
Anticancer Res; 2005; 25(4):2943-50. PubMed ID: 16080548
[TBL] [Abstract][Full Text] [Related]
5. [Expression and prognostic significance of EphA2 and EphrinA-1 in ovarian serous carcinomas].
Han LP; Liu JF; Liu XR; Dong ZM; Suo ZH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):179-84. PubMed ID: 21500549
[TBL] [Abstract][Full Text] [Related]
6. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
[TBL] [Abstract][Full Text] [Related]
7. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma.
Shigemasa K; Gu L; O'Brien TJ; Ohama K
Clin Cancer Res; 2003 May; 9(5):1756-63. PubMed ID: 12738731
[TBL] [Abstract][Full Text] [Related]
8. EPHA2/EFNA1 expression in human gastric cancer.
Nakamura R; Kataoka H; Sato N; Kanamori M; Ihara M; Igarashi H; Ravshanov S; Wang YJ; Li ZY; Shimamura T; Kobayashi T; Konno H; Shinmura K; Tanaka M; Sugimura H
Cancer Sci; 2005 Jan; 96(1):42-7. PubMed ID: 15649254
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
10. [Correlation of EphA2 protein expression with clinicopathological characteristics and prognosis in laryngeal squamous cell carcinoma].
Liu Y; Zhang X; Qiu YZ; Huang DH; Zhou XJ; Tan PQ; Cai GM; Dai YZ; Yu CY; Xiao JY; Tian YQ
Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):197-201. PubMed ID: 21575519
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
12. Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis.
Saito T; Masuda N; Miyazaki T; Kanoh K; Suzuki H; Shimura T; Asao T; Kuwano H
Oncol Rep; 2004 Mar; 11(3):605-11. PubMed ID: 14767510
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.
Koensgen D; Mustea A; Denkert C; Sun PM; Lichtenegger W; Sehouli J
Anticancer Res; 2006; 26(2C):1683-9. PubMed ID: 16617562
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma.
Luo LY; Katsaros D; Scorilas A; Fracchioli S; Piccinno R; Rigault de la Longrais IA; Howarth DJ; Diamandis EP
Clin Cancer Res; 2001 Aug; 7(8):2372-9. PubMed ID: 11489815
[TBL] [Abstract][Full Text] [Related]
15. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
Rosen DG; Wang L; Jain AN; Lu KH; Luo RZ; Yu Y; Liu J; Bast RC
Clin Cancer Res; 2004 Oct; 10(19):6559-66. PubMed ID: 15475444
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma.
Wu D; Suo Z; Kristensen GB; Li S; Troen G; Holm R; Nesland JM
Gynecol Oncol; 2004 Aug; 94(2):312-9. PubMed ID: 15297167
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.
Han LY; Landen CN; Kamat AA; Lopez A; Bender DP; Mueller P; Schmandt R; Gershenson DM; Sood AK
J Clin Oncol; 2006 Feb; 24(5):755-61. PubMed ID: 16380413
[TBL] [Abstract][Full Text] [Related]
18. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
19. ErbB-3 predicts survival in ovarian cancer.
Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]